TABLE 2.
Effects of CT, LT-IIa, and LT-IIb on CD40L expression by human PBMCa
| Stimulant | Toxin (100 ng/ml) | Mean % CD40L-positive cells ± SD at:
|
|||
|---|---|---|---|---|---|
| 2 h | 4 h | 6 h | 24 h | ||
| None | None | 1.81 ± 0.93 | 2.24 ± 1.27 | 1.16 ± 0.64 | 1.32 ± 0.47 |
| Anti-CD3 | None | 28.39 ± 7.49 | 37.41 ± 9.21 | 33.18 ± 8.77 | 5.35 ± 3.88 |
| CT | 11.06 ± 3.94* | 15.41 ± 5.57* | 14.22 ± 4.69* | 2.88 ± 1.31 | |
| LT-IIa | 27.61 ± 6.08 | 35.68 ± 4.49 | 32.15 ± 6.77 | 5.19 ± 3.35 | |
| LT-IIb | 23.83 ± 4.12 | 33.19 ± 6.27 | 31.59 ± 4.13 | 4.93 ± 2.17 | |
a
The data represent the means of cultures derived from four donors. *, significant difference at P < 0.05 compared to anti-CD3-treated PBMC. Percent positive staining for IgG1 isotype control (CD25 and CD69) was 0.59% ± 0.14%.